Merck has finalized its acquisition of Prometheus Biosciences for $10.8 billion, gaining five candidates for inflammatory bowel and immune-mediated diseases, including the leading candidate MK-7240 for ulcerative colitis and Crohn's disease. The purchase marks Merck's further expansion into the immunology space. The all-cash agreement includes buying all outstanding shares of Prometheus at a 75%..
Merck & Co has acquired Prometheus Biosciences, Inc. for $10.8 billion, making it a wholly-owned subsidiary and helping Merck expand its presence in immunology while strengthening its pipeline with a potential best-in-class candidate for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. The leading clinical candidate, PRA-023, is now known as MK-7240 and is a humanized mon..
